Stock Analysis of Allovir Inc (ALVR) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ALVR
Close 0.775
Change 0.0240 / 3.19 %
Volume 183904
Vol Change 9252.00 / 5.30 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index No Significant Stability


Fundamental View of Allovir Inc
PE (TTM)

-102.54

Very Poor
Price / Book

104.10

Very Poor
Price / Sales

2196.85

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

89173.33 K

Enterprise Value

9833.33 K

ROA (TTM)

-80.87

Very Poor
ROE (TTM)

-101.52

Very Poor
Net Margin (TTM)

-2142.41

Very Poor
Revenue

%

0
Net Profit

0.088 %

-168858.00 K
Debt to Equity

0.074

Excellent
Altman Z Score

-5.55

Very Poor
Quick Ratio

0

Poor
Cash Ratio

6.48

Excellent


Highs/Lows of Allovir Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.7855 1.29 % 1.54 % 0.8080.5813-May-2413-May-24
Two Week0.798 2.83 % 3.42 % 0.820.5809-May-2413-May-24
One Month0.7569 2.44 % 5.60 % 0.8250.5823-Apr-2413-May-24
Three Month0.7 10.77 % 5.95 % 0.850.5801-Apr-2413-May-24
Six Months1.63 52.43 % 17.48 % 2.4850.5814-Dec-2313-May-24
One year4.15 81.32 % 27.52 % 6.10.5807-Jun-2313-May-24
Two year4.6 83.14 % 29.70 % 10.290.5818-Oct-2213-May-24


Technical View of Allovir Inc
RSI

49.98

Neutral
MACD

-0.0005

Strong Bearish
ADX

31.50

Bearish
Super Trend

0.826

Mild Bearish
Williams %R

-18.58

Mild Bearish
CCI

-64.17

Neutral


EMA 5

0.767

Strong Bullish
EMA 15

0.776

Mild Bearish
EMA 50

0.787

Whipsaw
EMA 100

0.962

Mild Bearish
SMA 100

0.732

Whipsaw
SMA 200

1.46

Mild Bearish
SMA 5 / 20

0.760 / 0.787

Strong Bearish
SMA 15 / 50

0.787 / 0.766

Bullish
SMA 50 / 200

0.766 / 1.46

Mild Bearish




Charts of Allovir Inc


Returns of Allovir Inc with Peers
Period / StockALVRANIXBWAYBNTC
1 Week-1.29%-5.00%0.938%2.59%
1 Mth2.44%-6.56%6.53%97.71%
3 Mth10.77%-29.63%-20.65%218.56%
6mth-52.43%-3.39%13.03%176.68%
1 Year-81.32%-16.91%241.59%193.81%
2 Year-83.14%-15.93%-17.23%-46.83%
5 Years--33.26%-50.56%-97.99%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Allovir Inc with Peers
Ratio / StockALVRANIXBWAYBNTC
PE-102.54-8.46-67.13-236.50
P/B104.103.562.51425.18
ROA-80.87-39.26-2.68-128.98
ROE-101.52-40.57-3.96-179.78
Debt To Equity0.0740.00210.00561.36
Revenue0
% 		210000
99.99 % 		28789.00 K
5.93 % 		75000.00
2.74 %
Net Income-168858.00 K
0.088 % 		-9811.00 K
27.83 % 		-8191.00 K
38.64 % 		-19562.00 K
7.44 %


Technicals of Allovir Inc with Peers
Technical / StockALVRANIXBWAYBNTC-
ADX31.5018.6314.2853.41
CMF0.326-0.315-0.3120.214
MFI25.6635.7440.5069.52
RSI49.9841.4548.6966.16
MACD Abv SignalFalseTrueFalseTrue
Price Above 50 MATrueFalseFalseTrue-
Price Above 200 MAFalseFalseTrueTrue-


About : Allovir Inc

Address : 1100 Winter Street, Waltham, MA, United States, 02451
Tel : 617 433 2605
URL : https://www.allovir.com
Code : ALVR, ISIN : US0198181036, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 30_Jul_2020
Employee Count : 15

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)